Nexien BioPharma Inc (NXEN)
OTHER OTC:NXEN
US Market

Nexien BioPharma (NXEN) Income Statement

5 Followers

Nexien BioPharma Income Statement

Last quarter (Q ), Nexien BioPharma's total revenue was $0.00, a decrease of ― from the same quarter last year. In Q, Nexien BioPharma's net income was $-93.59K. See Nexien BioPharma’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Jun 22Jun 21Jun 20Jun 19Jun 18
Total Revenue
-$ 0.00$ 0.00$ 0.00$ 0.00$ 0.00
Cost of Revenue
------
Gross Profit
------
Operating Expense
$ 382.90K$ 563.99K$ 1.84M$ 2.64M$ 3.93M$ 1.28M
Operating Income
$ -382.90K$ -563.99K$ -1.84M$ -2.64M$ -3.93M$ -1.28M
Net Non Operating Interest Income Expense
$ -90.01K$ -62.37K$ -16.18K$ -33.00$ 0.00-
Other Income Expense
---$ -35.00K$ -367.92K-
Pretax Income
$ -472.92K$ -626.36K$ -1.86M$ -2.67M$ -4.30M$ -1.28M
Tax Provision
------
Earnings From Equity Interest Net Of Tax
------
Net Income Common Stockholders
$ -472.92K$ -626.36K$ -1.86M$ -2.67M$ -4.30M$ -1.28M
Basic EPS
$ >-0.01$ -0.01$ -0.03$ -0.05$ -0.08$ -0.03
Diluted EPS
$ >-0.01$ -0.01$ -0.03$ -0.05$ -0.08$ -0.03
Basic Average Shares
$ 242.48M$ 57.86M$ 55.40M$ 53.91M$ 51.03M$ 42.67M
Diluted Average Shares
$ 242.48M$ 57.86M$ 55.40M$ 53.91M$ 51.03M$ 42.67M
Dividend Per Share
------
Total Operating Income As Reported
------
Reported Normalized Basic E P S
------
Reported Normalized Diluted E P S
------
Rent Expense Supplemental
------
Total Expenses
$ 382.90K$ 563.99K$ 1.84M$ 2.64M$ 3.93M$ 1.28M
Net Income From Continuing And Discontinued Operation
$ -472.92K$ -626.36K$ -1.86M$ -2.67M$ -4.30M$ -1.28M
Normalized Income
$ -472.92K$ -626.36K$ -1.86M$ -2.64M$ -3.93M$ -1.28M
Interest Expense
$ 90.01K$ 62.37K$ 16.18K$ 33.00$ 0.00-
EBIT
$ -382.90K$ -563.99K$ -1.84M$ -2.67M$ -4.30M$ -1.28M
EBITDA
$ -382.90K$ -563.99K$ -1.84M$ -2.67M$ -4.30M$ -1.28M
Currency in USD

Nexien BioPharma Earnings and Revenue History

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis